Loading…
← CockpitCompetitor Analysis › 300952.SZ Jiangsu Hanvo Safety Product Co. Ltd. Class AOpen in the cockpit ↗

Jiangsu Hanvo Safety Product Co. Ltd. Class A300952.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 65
Mkt cap
$575M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$45.3M
20-day average traded
Fwd P/E
39.7×
forward earnings
ROIC−WACC
-1.3 pp
WACC 7.2%
Hurdle
n/a
no reverse DCF
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥16.42
1D-4.9%
1W-21.8%
1M+2.0%
3M-4.0%
6M-38.2%
YTD-43.8%
1Y-27.6%
ATR %9.0%
52w lowhigh59.0% off high

What Jiangsu Hanvo Safety Product does

Employees: 2,691

Jiangsu Hanvo Safety Product at a glance

Size Jiangsu Hanvo Safety Product (300952.SZ) is a China Health Care company (Medical Specialties) with a market value of $575M, the 3353rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.42 on 18 Nov 2026.

Performance Over six months the shares fell 38.2%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 19 in its peer set.

Growth Revenue grew 6.5% over the last twelve months (peer median +14.4%); the operating margin is 7.5% (peer median 6.5%).

Valuation It trades at 39.7× forward earnings against a peer median of 23.5× (3rd most expensive of 10).

Capital Return on invested capital runs 1.3 points below its cost of capital (7.2% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 102300952.SZ 63
Six months, rebased to 100: Jiangsu Hanvo Safety Product against the median of its 20 peers (local-currency closes).

Jiangsu Hanvo Safety Product financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.35BCN¥1.22BCN¥1.27BCN¥967MCN¥889M
Revenue growth—-3%+31%+9%—
Gross profitCN¥400MCN¥275MCN¥265MCN¥225MCN¥210M
EBITDAn/aCN¥234MCN¥201MCN¥176MCN¥153M
Net incomeCN¥70.1MCN¥102MCN¥117MCN¥106MCN¥122M
Free cash flow-CN¥178M-CN¥381M-CN¥229M-CN¥113M-CN¥128M
Capital expenditureCN¥389MCN¥580MCN¥332MCN¥216MCN¥318M
Total debtCN¥774MCN¥579MCN¥736MCN¥285MCN¥110M

Quarterly statements and history in the cockpit →

Jiangsu Hanvo Safety Product competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%PACB301235OBIO603122300314688581TCMDSGHTNAN300869ZJYLMYGNRCEL300952.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Hanvo Safety Product is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×301235300314688581TCMDMEDINAN605369XVIVO688236300952.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Hanvo Safety Product is the large dot.

Jiangsu Hanvo Safety Product competitors and peer comparison

How Jiangsu Hanvo Safety Product compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Hanvo Safety Product against its 20 peers (data as of 18 Nov 2026)
Measure300952.SZPeer medianRank in peer set
1-month return+2.0%-1.9%8th highest of 19
6-month return-38.2%+3.2%2nd lowest of 19
Distance from 52-week high-59.0%-31.6%3rd lowest of 20
Revenue growth (TTM)+6.5%+14.4%10th lowest of 20
Operating margin7.5%6.5%9th highest of 20
Forward P/E39.7×23.5×3rd most expensive of 10
ROIC minus cost of capital-1.3 pp-5.4 pp9th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%

Questions

Which companies are Jiangsu Hanvo Safety Product's closest peers?
The cockpit's peer set: Pacific Biosciences of California (PACB), Wuhan Huakang Century Clean Technology (301235.SZ), Orchestra BioMed (OBIO), Cowealth Medical China (603122.SS), Ningbo David Medical Device (300314.SZ), Hangzhou AGS MedTech (688581.SS), Tactile Systems Technology (TCMD), vVARDIS (VVVV).
Is Jiangsu Hanvo Safety Product expensive compared with its peers?
On forward p/e it trades at 39.7× against a peer median of 23.5×, 3rd most expensive of 10 in its peer set.
How has Jiangsu Hanvo Safety Product stock performed?
Over six months to 18 Nov 2026 the shares returned -38.2% against +3.2% for the median peer; over one year -27.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.